Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Douillard, Jean‐Yves; S. Oliner, Kelly; Siena, Salvatore; Tabernero, Josep; L. Burkes, Ronald; Barugel, Mario; Humblet, Yves; Bodoky, G.; Cunningham, David; Jassem, Jacek; Rivera, Fernando; Kocáková, Ilona; Ruff, Paul; Błasińska-Morawiec, Maria; Šmakal, Martin; Luc Canon, Jean; Rother, M.; T. Williams, Richard; Rong, Alan; S. Wiezorek, Jeffrey; Sidhu, Roger; D. Patterson, Scott

doi:10.1056/nejmoa1305275

Public

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Published in New England Journal of Medicine • Sep 11, 2013

Authors:

Jean‐Yves Douillard

Kelly S. Oliner

Salvatore Siena

Abstract

BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrosp...

Subject

KRAS

Panitumumab

Neuroblastoma RAS viral oncogene homolog

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!